Proactive Investors – by Mourad Haroutunian
AstraZeneca Plc (NYSE:AZN) advanced in New York trading after the second-largest U.K. drugmaker agreed to pay Inovio Pharmaceuticals (NASDAQ:INO) as much as $727.5 million for rights to an experimental cancer vaccine.
ADRs of the London-based company added 1 percent to $34.03 at 11:57 a.m. in New York, expanding gains this month to 2.4 percent. Shares of Inovio leaped 23 percent to $7.92. Continue reading “AstraZeneca to pay Inovio Pharma $727 mln to produce cancer vaccine”